Non-surgical management of advanced ovarian cancer with maintenance PARP inhibitors
The standard of care for advanced ovarian cancer is cytoreductive surgery followed by a platinum-taxane combination with PARP inhibition as a maintenance strategy. In practice, many advanced ovarian cancer patients are older and are either not candidates for surgery or decline surgical intervention....
Saved in:
Main Authors: | Taliya Lantsman (Author), Lily Jia (Author), Meghan Shea (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
by: Lili Gao, et al.
Published: (2021) -
Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC
by: Taliya Lantsman, et al.
Published: (2022) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018) -
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
by: Anastasia Navitski, et al.
Published: (2021)